The CRISPR–Cas9
system is able to recognize target sequences based purely on nucleotide
sequences, and it has been adapted for genome editing in both eukaryotes and
prokaryotes. Recently, a new family of CRISPR-based genome-editing methods,
named base-editor techniques, was developed. Because current base-editing
techniques can only facilitate C-to-T editing and A-to-G editing, a complete
base-editing technique for converting any base to any other base is highly
desirable.
In the paper published in Nature Biotechnology by Dr. Changhao Bi’s team and Dr. Xueli Zhang’s team at Tianjin Institute of Industrial Biotechnology on July 20, 2020, they present BEs that cause C-to-A transversions in Escherichia coli and C-to-G transversions in mammalian cells. All plasmids of this article have been deposited on MolecularCloud (Dongdong Zhao, et al., 2020).
These glycosylase base editors (GBEs) consist
of a Cas9 nickase, a cytidine deaminase and a uracil-DNA glycosylase (Ung). Ung
excises the U base created by the deaminase, forming an apurinic/apyrimidinic
(AP) site that initiates the DNA repair process.
In E. coli, they used activation-induced cytidine deaminase (AID) to construct AID-nCas9-Ung and found that it converts C to A with an average editing specificity of 93.8% ± 4.8% and editing efficiency of 87.2% ± 6.9%. When used in mammalian cells, they replaced AID with rat APOBEC1 (APOBEC-nCas9-Ung). They tested APOBEC-nCas9-Ung at 30 endogenous sites, and they observed C-to-G conversions with a high editing specificity at the sixth position of the protospacer between 29.7% and 92.2% and an editing efficiency between 5.3% and 53.0%. APOBEC-nCas9-Ung supplements the current adenine and cytidine BEs (ABE and CBE, respectively) and could be used to target G/C disease-causing mutations.
Table 1. Plasmids from this article
MC Cat No. |
Plasmid Name |
Description |
MC_0101154 |
HEK293T
expression of APOBEC_nCas9_Ung |
|
MC_0101155 |
HEK293T
expression, gRNAs targeting RNF2-site2 |
|
MC_0101156 |
HEK293T
expression, gRNAs targeting RNF2-site3 |
|
MC_0101157 |
HEK293T
expression, gRNAs targeting EMX1-site1 |
|
MC_0101158 |
HEK293T
expression, gRNAs targeting EMX1-site4 |
|
MC_0101159 |
HEK293T
expression, gRNAs targeting EMX1-site5 |
|
MC_0101160 |
HEK293T
expression, gRNAs targeting EMX1-site6 |
|
MC_0101162 |
HEK293T
expression, gRNAs targeting FANCF-site4 |
|
MC_0101163 |
HEK293T
expression, gRNAs targeting RP11-177B4-1 |
|
MC_0101164 |
HEK293T
expression, gRNAs targeting RP11-177B4-2 |
|
MC_0101165 |
HEK293T
expression, gRNAs targeting RP11-177B4-3 |
|
MC_0101166 |
HEK293T
expression, gRNAs targeting RP11-177B4-4 |
|
MC_0101167 |
HEK293T
expression, gRNAs targeting PSMB2-1 |
|
MC_0101168 |
HEK293T
expression, gRNAs targeting PSMB2-2 |
|
MC_0101169 |
HEK293T
expression, gRNAs targeting VISTAhs267 |
|
MC_0101170 |
HEK293T
expression, gRNAs targeting KLF4-1 |
|
MC_0101171 |
HEK293T
expression, gRNAs targeting KLF4-2 |
|
MC_0101172 |
HEK293T
expression, gRNAs targeting VEGFA-3 |
|
MC_0101173 |
HEK293T
expression, gRNAs targeting DNMT3B-OTS1 |
|
MC_0101174 |
HEK293T
expression, gRNAs targeting HEK2 OT1 |
|
MC_0101175 |
HEK293T
expression, gRNAs targeting HEK2 OT2 |
|
MC_0101176 |
HEK293T
expression, gRNAs targeting HEK2 OT3 |
|
MC_0101177 |
HEK293T
expression, gRNAs targeting HEK4 OT1 |
|
MC_0101178 |
HEK293T
expression, gRNAs targeting HEK4 OT2 |
|
MC_0101179 |
HEK293T
expression, gRNAs targeting HIRA-1 |
|
MC_0101180 |
HEK293T
expression, gRNAs targeting HIRA-2 |
|
MC_0101181 |
HEK293T
expression, gRNAs targeting NIBAN1 |
|
MC_0101182 |
HEK293T
expression, gRNAs targeting RP1-97D16 |
|
MC_0101183 |
E.coli
expression of nCas9_AID |
|
MC_0101184 |
E.coli
expression of Ung-nCas9-AID |
|
MC_0101185 |
E.coli
expression, gRNAs targeting lacZ1444-1463(apramycin resistance) |
Limited-time
promotion-September only!
Share your ideas
about this paper, base editing, or gene editing technologies (~100
words) in the comment section below, to get one of the above plasmids FOR FREE!
About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2024 MolecularCloud